8a-Phenyldecahydroquinoline (8A-PDHQ) is a high affinity
NMDA antagonist developed by a team at Parke Davis in the 1950s.[1] It is a structural analog of
phencyclidine with slightly lower binding affinity than the parent compound. (−)-8a-Phenyldecahydroquinoline has an in vivo potency comparable to that of (+)-
MK-801.[2][3]
^Chen C, Kozikowski AP, Wood PL, Reynolds IJ, Ball RG, Pang YP (May 1992). "Synthesis and biological activity of 8a-phenyldecahydroquinolines as probes of PCP's binding conformation. A new PCP-like compound with increased in vivo potency". Journal of Medicinal Chemistry. 35 (9): 1634–8.
doi:
10.1021/jm00087a020.
PMID1315871.
^Elhallaoui M, Laguerre M, Carpy A, Ouazzani FC (February 2002). "Molecular modeling of noncompetitive antagonists of the NMDA receptor: proposal of a pharmacophore and a description of the interaction mode". Journal of Molecular Modeling. 8 (2): 65–72.
doi:
10.1007/s00894-001-0067-4.
PMID12032600.
S2CID34882820.